

# György Bodoky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5104906/publications.pdf>

Version: 2024-02-01

99  
papers

26,299  
citations

53751

45  
h-index

39638

94  
g-index

104  
all docs

104  
docs citations

104  
times ranked

24080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 1408-1417.	13.9	3,543
2	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	6.3	2,771
3	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
4	Panitumumabâ€“FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1023-1034.	13.9	1,971
5	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1224-1235.	5.1	1,932
6	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4697-4705.	0.8	1,644
7	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	0.6	1,233
8	Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 466-474.	0.8	1,048
9	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	6.3	878
10	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2015, 16, 499-508.	5.1	753
11	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 490-499.	5.1	740
12	ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. <i>Clinical Nutrition</i> , 2006, 25, 245-259.	2.3	665
13	Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 2212-2217.	0.8	543
14	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1547-1553.	0.8	498
15	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2012, 13, 1225-1233.	5.1	484
16	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 1346-1355.	0.6	462
17	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009, 27, 3117-3125.	0.8	437
18	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology, The</i> , 2017, 18, 640-653.	5.1	383

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 931-945.	5.1	337
20	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	1.8	270
21	CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. <i>Lancet Oncology</i> , The, 2008, 9, 132-138.	5.1	210
22	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) in patients who have failed first-line gemcitabine therapy. <i>Investigational New Drugs</i> , 2012, 30, 1216-1223.	1.2	196
23	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3595.	0.8	194
24	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
25	Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1997-2003.	0.8	161
26	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. <i>Annals of Oncology</i> , 2015, 26, 921-927.	0.6	132
27	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). <i>Annals of Oncology</i> , 2016, 27, 856-861.	0.6	107
28	Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia. <i>Journal of the National Cancer Institute</i> , 2006, 98, 273-284.	3.0	97
29	Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial (SAKK 44/00) (CECOG/PAN.1.3.001). <i>Journal of Clinical Oncology</i> , 2008, 26, 3695-3701.	0.8	93
30	Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). <i>Oncologist</i> , 2010, 15, 285-292.	1.9	93
31	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. <i>Annals of Oncology</i> , 2012, 23, 1214-1222.	0.6	91
32	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. <i>Annals of Oncology</i> , 2018, 29, 602-609.	0.6	83
33	Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. <i>Annals of Oncology</i> , 2013, 24, 718-725.	0.6	81
34	Effect of enteral nutrition on exocrine pancreatic function. <i>American Journal of Surgery</i> , 1991, 161, 144-148.	0.9	79
35	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. <i>European Journal of Cancer</i> , 2013, 49, 3616-3624.	1.3	78
36	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. <i>British Journal of Cancer</i> , 2007, 97, 1469-1474.	2.9	77

#	ARTICLE	IF	CITATIONS
37	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. <i>European Journal of Cancer</i> , 2009, 45, 1589-1596.	1.3	66
38	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , 2016, 27, 673-679.	0.6	62
39	Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. <i>Annals of Oncology</i> , 2013, 24, 710-718.	0.6	57
40	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , 2016, 27, 2082-2089.	0.6	56
41	Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4544-4550.	0.8	55
42	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017, 17, 132.	0.9	54
43	Cancer epidemiology in Central and South Eastern European countries. <i>Croatian Medical Journal</i> , 2011, 52, 478-487.	0.2	53
44	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISEâ€”a global phase III study. <i>Annals of Oncology</i> , 2019, 30, 124-131.	0.6	52
45	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, 354-361.	0.6	50
46	Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2014, 62, 547-555.	1.3	45
47	Tricellulin expression in normal and neoplastic human pancreas. <i>Histopathology</i> , 2012, 60, E76-86.	1.6	42
48	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2215-2222.	1.9	41
49	Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. <i>Oncologist</i> , 2016, 21, 1183-1190.	1.9	37
50	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36
51	Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. <i>British Journal of Cancer</i> , 2010, 103, 1318-1324.	2.9	33
52	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). <i>Journal of Clinical Oncology</i> , 2021, 39, 990-1000.	0.8	30
53	Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. <i>Journal of Clinical Oncology</i> , 2009, 27, 4511-4511.	0.8	24
54	The Activated Targets of mTOR Signaling Pathway Are Characteristic for PDGFRA Mutant and Wild-type Rather Than KIT Mutant GISTs. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 22-33.	2.1	23

#	ARTICLE	IF	CITATIONS
55	Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 62-75.	0.5	22
56	Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.. <i>Pathology and Oncology Research</i> , 2017, 23, 753-759.	0.9	20
57	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. <i>Annals of Oncology</i> , 2020, 31, 246-256.	0.6	20
58	Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. <i>Oncologist</i> , 2019, 24, e30-e37.	1.9	19
59	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1143-1157.	2.7	19
60	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 599-608.	1.1	18
61	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	1.4	18
62	Effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by <sup>31</sup> P-NMR. <i>Physiology and Behavior</i> , 1995, 58, 521-527.	1.0	16
63	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). <i>European Journal of Cancer</i> , 2018, 89, 82-89.	1.3	16
64	Rectal Cancer Therapy: Decision Making on Basis of Quality of Life?. <i>Zentralblatt Fur Chirurgie</i> , 2004, 129, 139-148.	0.3	15
65	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 109-117.	0.6	15
66	Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. <i>ESMO Open</i> , 2016, 1, e000041.	2.0	15
67	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , 2018, 3, e000347.	2.0	15
68	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. <i>ESMO Open</i> , 2020, 5, e000662.	2.0	15
69	Clinical Benefit Response in Pancreatic Cancer Trials Revisited. <i>Oncology Research and Treatment</i> , 2014, 37, 1-1.	0.8	14
70	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015, 11, 2553-2562.	1.1	13
71	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591881835.	1.4	13
72	Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, LBA8284-LBA8284.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Effects of different types of isocaloric parenteral nutrients on food intake and metabolic concomitants. <i>Physiology and Behavior</i> , 1995, 58, 75-79.	1.0	9
74	Basics in clinical nutrition: Complications of enteral nutrition. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2009, 4, e209-e211.	0.4	9
75	Ileocolic Anastomotic Ulcer after Surgery in Adulthood: Case Report and Review of the Literature. <i>Zeitschrift Fur Gastroenterologie</i> , 2004, 42, 605-608.	0.2	8
76	Nocturnal cyclic versus continuous total parenteral nutrition: Food intake and feeding pattern in rats. <i>Physiology and Behavior</i> , 1992, 51, 431-435.	1.0	7
77	The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. <i>Cancer</i> , 2000, 89, 177-80.	2.0	7
78	State of artificial nutrition in Hungary: standpoint and methodologic recommendations. <i>Nutrition</i> , 1999, 15, 40-43.	1.1	5
79	Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results. <i>Annals of Oncology</i> , 2012, 23, ix224-ix225.	0.6	4
80	Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study. <i>Annals of Oncology</i> , 2017, 28, v188-v189.	0.6	4
81	Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. <i>Pathology and Oncology Research</i> , 2019, 25, 149-156.	0.9	4
82	Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2201-2207.	0.9	4
83	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	1.9	4
84	The effect of jejunal nutrition on pancreatic exocrine function. <i>Acta Chirurgica Hungarica</i> , 1992, 33, 13-21.	0.0	4
85	The comparative effects of abrupt vs. stepwise discontinuation of TPN in rats. <i>Physiology and Behavior</i> , 1992, 52, 591-595.	1.0	3
86	3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II&III COC patients (PETACC 3&EORTC 40993&SAKK 60/00). <i>European Journal of Cancer, Supplement</i> , 2007, 5, 239.	2.2	2
87	The effect of early postoperative nutrition on exocrine pancreatic function. <i>Acta Chirurgica Hungarica</i> , 1992, 33, 23-35.	0.0	2
88	Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. <i>Annals of Oncology</i> , 2014, 25, iv269.	0.6	1
89	Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, iv40.	0.6	1
90	Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI. <i>Annals of Oncology</i> , 2016, 27, vi198.	0.6	1

#	ARTICLE	IF	CITATIONS
91	The method of early postoperative alimentation by needle-catheter jejunostomy. Acta Chirurgica Hungarica, 1989, 30, 55-61.	0.0	1
92	P-0073 GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment with Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 7	0.6	0
93	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC). Annals of Oncology, 2013, 24, iv23-iv24.	0.6	0
94	PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4±Panitumumab in RAS wild-type metastatic colorectal carcinoma. Annals of Oncology, 2016, 27, ii1110.	0.6	0
95	PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial. Annals of Oncology, 2016, 27, ii1113.	0.6	0
96	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy. Annals of Oncology, 2017, 28, x67-x68.	0.6	0
97	The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology, 2018, 29, v42.	0.6	0
98	Effect of Dose Reductions on Response to 500-1¼g Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.. Blood, 2005, 106, 3558-3558.	0.6	0
99	An up-to-date method of early postoperative enteral feeding. Acta Paediatrica Hungarica, 1987, 28, 51-7.	0.0	0